
What the $1b Roche-PathAI Deal Can Tell Clinical Lab Directors
Roche acquires a workflow rather than a company, says AI industry observer

Roche acquires a workflow rather than a company, says AI industry observer

Natera’s assay focuses on the need for adjuvant therapy, while Valar’s test stratifies risk of recurrence

But anti-regulatory stance taken by Trump administration could serve as a potential obstacle in the effort

Advances could signal changes for clinical laboratories and at-home testing

Part of our Revenue Cycle Management Webinar Series, this event explores how AI and automation can enhance clinical lab billing and coding